Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: dates

Transgene reports business update and end Q3 2020 financial position

20201105 Transgene Q3 business upradta EN

Published 5 November 2020
Categorized as 2020, Press release

Transgene Presents its Individualized Immunotherapy, TG4050, at the Annual Neoantigen Based Therapies Summit

20201105 TG – Neoantigen summit presentation

Published 5 November 2020
Categorized as 2020, Press release, TG4050

Transgene announces detailed results from clinical study of TG4001 in combination with avelumab in advanced HPV-positive cancers

20201027 – TG4001+avelumab abstract data SITC – EN

Published 27 October 2020
Categorized as 2020, Press release, TG4001, TG4001

Acceptance of Late Breaking Abstract at Upcoming SITC 2020 Conference, on the detailed results from clinical study of TG4001 in combination with avelumab in advanced HPV-positive cancers

20201019 TG4001+avelumab SITC – EN

Published 19 October 2020
Categorized as 2020, Press release, TG4001, TG4001

Transgene and BioInvent to present data on oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting

20201015 – BT-001_SITC poster EN

Published 15 October 2020
Categorized as 2020, BT-001, Press release

Transgene, NEC and BostonGene Announce Strategic Collaboration for Two Ongoing Clinical Trials for Patients with Ovarian and Head & Neck Cancers

20201006 Transgene_NEC_BostonGene_Press_Release_final

Published 6 October 2020
Categorized as 2020, Myvac, Press release, TG4050

Positive clinical results for TG4001 and TG6002 and financial visibility secured until 2022

20200916 Results H1 2020 EN

Published 16 September 2020
Categorized as 2020, Press release

Transgene Announces Upcoming Investor Meetings

20200909 Next investor events

Published 9 September 2020
Categorized as 2020, Press release

Positive initial data from a Phase 1 trial with Transgene’s oncolytic virus TG6002

20200908 Transgene TG6002 Phase 1 EN

Published 8 September 2020
Categorized as -others, 2020, Invir.IO, Press release, TG6002

Preclinical Evaluation of the Oncolytic Vaccinia Virus TG6002 by Translational Research on Canine Breast Cancer

Jérémy Béguin, et al.Molecular Therapy Oncolytics, September 2020 – Read the articlePublication

Published 2 September 2020
Categorized as 2020, Publication, TG6002

Posts pagination

Newer posts Page 1 … Page 24 … Page 47 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu